Working… Menu

STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00126360
Recruitment Status : Unknown
Verified August 2005 by St George Hospital, Australia.
Recruitment status was:  Recruiting
First Posted : August 3, 2005
Last Update Posted : November 10, 2005
Information provided by:
St George Hospital, Australia

Brief Summary:
This is a randomized study comparing the use of Anastrozole before and continuing during radiotherapy for breast cancer compared to the use of anastrozole after irradiation.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Timing of Anastrozole in respect to radiotherapy Phase 4

Detailed Description:

Adjuvant radiotherapy is well established as the primary modality to enhance local control in breast cancer. The use of adjuvant hormone therapy such as tamoxifen has shown to improve local control to a relatively minor amount on its own and does enhance local control of adjuvant radiotherapy. There is however, conflicting in vitro and clinical data regarding the effects of different sequences on tamoxifen and radiotherapy in terms of both local control and enhancement of radiotherapy toxicities.

Aromatase inhibitors such as anastrazole are establishing themselves as a class of drug superior to tamoxifen for the control of estrogen dependent breast cancers and overall are better tolerated with the exception of greater bone loss.

As the key question is whether the sequencing of the aromatase inhibitor anastrozole alters local control by acting as an enhancer of the radiation breast cancer cell kill, it is therefore the aim of this study to compare 3 months of anastrozole prior to radiotherapy versus 3 months of anastrozole after radiotherapy with a specific objective of reducing the baseline ratio of in- field radiotherapy failure from 6% to 3%.This pilot study is preliminary to a planned long term study to investigate local failure.

For the pilot a period of 6 months with all contributing centres open will provide a good test of recruitment matching estimates. 100 patients will provide a good sample to compare to the 270 tamoxifen treated women in the breast boost study for quality of life. It will also provide a 95% CI on the proportion of complying women in the order of ± 5% if 85 to 90 % of women comply.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot for a Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Ant-Oestrogen Therapy Delayed Until After Radiotherapy
Study Start Date : August 2005
Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Anastrozole

Primary Outcome Measures :
  1. Local failure within irradiation volume

Secondary Outcome Measures :
  1. Early quality of life
  2. Lung fibrosis
  3. Also demonstration of recruitment capacity at lead trial centres

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or more years. No upper limit.
  • Post total mastectomy or lumpectomy. All planned surgery complete.
  • Margins clear (no tumour contacting the inked margin)
  • Tumour oestrogen or progesterone receptor positive
  • Planned dose to irradiated volumes at least the biological equivalent of 45 Gy in 25 fractions or more.
  • ECOG 0-2
  • Patients post menopausal using same criteria as ATAC study.
  • Written informed consent

Exclusion Criteria:

  • Previous radiotherapy to the area to be treated.
  • Previous invasive malignancy within 5 years of current breast cancer diagnosis with the exception of cervix in-situ or skin cancer other than melanoma.
  • Patients with clinical evidence of metastatic disease.
  • Previous hormonal breast therapy.
  • Ongoing hormone replacement therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00126360

Layout table for location contacts
Contact: Ass. Prof. Peter H Graham, MBBS FRANZCR +61 293503934

Layout table for location information
Australia, New South Wales
Liverpool Hospital Not yet recruiting
Sydney, New South Wales, Australia, 2170
Contact: Dr Geoff Delaney, MBBS FRANZCR    +61 29828 5276   
Principal Investigator: Dr Geoff Delaney, MBBS FRANZCR         
St George Hospital Recruiting
Sydney, New South Wales, Australia, 2217
Contact: Peter Graham, MBBS FRANZCR    +61 2 9350 3912   
Campbelltown Hospital Not yet recruiting
Sydney, New South Wales, Australia, 2560
Contact: Dr George Papadatos, MBBS FRANZCR    +61 246344355   
Principal Investigator: Dr George Papadatos, MBBS FRANZCR         
Australia, Queensland
Princess Alexandra Hospital Not yet recruiting
Brisbane, Queensland, Australia, 4102
Contact: Dr Jennifer Harvey, MBBS FRANZCR    +61 732402 111   
Principal Investigator: Dr Jennifer Harvey, MBBS FRANZCR         
Sponsors and Collaborators
St George Hospital, Australia
Layout table for investigator information
Principal Investigator: Ass. Prof. Peter H Graham, MBBS FRANZCR Cancer Care Centre, St George Hospital, Sydney
Layout table for additonal information Identifier: NCT00126360    
Other Study ID Numbers: STARS-Pilot (05/55 Graham)
First Posted: August 3, 2005    Key Record Dates
Last Update Posted: November 10, 2005
Last Verified: August 2005
Keywords provided by St George Hospital, Australia:
Breast Cancer
Timing of Radiotherapy
Local Control
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs